NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

C型肝炎:競爭情形(2021年)

Hepatitis C - Competitive Landscape in 2021

出版商 GlobalData 商品編碼 1022619
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
C型肝炎:競爭情形(2021年) Hepatitis C - Competitive Landscape in 2021
出版日期: 2021年07月30日內容資訊: 英文 52 Pages
簡介

非結構蛋白質5A(NS5A)和5B(NS5B)成為在C型肝炎治療中醫藥品開發商的主要目標。現在開發138種藥物,其中90%處於初期階段。以Gilead Sciences公司為首大型製藥企業獨佔這個適應症的研究開發。新的直接作用型的抗病毒療法(DAAs)的使用頻率增加預期帶動市場,不過,患者數持續減少和新的抗病毒療法的成本高限制市場成長。

本報告提供C型肝炎的相關調查,C型肝炎治療關於現在及未來的競爭情形為焦點,疾病的流行病學,市售、開發平台藥物的評估,商業性評估,社群媒體和數位行銷相關資訊等彙整資料。

目錄

第1章 序文

  • 目錄
  • 簡稱
  • 相關報告
  • 今後的相關報告

第2章 摘要整理

  • 主要調查結果
  • 重要的活動

第3章 簡介

  • 調查範圍
  • 疾病、流行病學概要
  • 流行病學

第4章 成藥的評估

  • 成藥概要
  • 成藥的簡介

第5章 開發平台評估

  • 開發平台概要
  • 各地區的開發平台的明細
  • 分子類型及各目標的開發平台的明細
  • 醫藥品審查指定
  • 相變的成功率
  • 核準的可能性

第6章 臨床試驗的評估

  • 各階段的臨床試驗概要
  • 各地區的概要
  • 治療領域的觀點
  • 主要贊助商
  • 登記分析
  • 實行可能性分析

第7章 商業性評估

  • 今後的市場催化劑

第8章 社群媒體與數位行銷

  • Twitter、Chatter
  • 頂級品牌的網站
  • 信任來源和引用來源

第9章 附錄

  • 調查手法
  • 關於作者
  • 關於GlobalData
  • 諮詢方式
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC045CL

GlobalData's Hepatitis C - Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

In hepatitis C, Nonstructural proteins 5A (NS5A) and 5B (NS5B) are major targets of drug developers. There are 138 drugs in the pipeline with 90% molecules present in early stage development. Large Pharma dominates R&D in this indication, with Gilead Sciences leading the way. More frequent use of newer direct-acting antiviral therapies (DAAs) is expected to drive the market, but Steady decline in overall patient pool and high cost of newer DAAs are expected to limit the market growth.

This reports provides a data-driven overview of the current and future competitive landscape in hepaltitis C therapeutics.

Scope

Components of the report include -

  • Disease epidemiology
  • Marketed drugs assessment
  • Pipeline drugs assessment
  • Clinical trials assessment
  • Commercial assessment
  • Social media overview
  • Digital marketing overview

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Hepatitis C market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

  • 1.1 Table of Contents
  • 1.2 Abbreviations
  • 1.3 Related Reports
  • 1.4 Upcoming Related Reports

2 Executive Summary

  • 2.1 Key Findings
  • 2.2 Key Events

3 Introduction

  • 3.1 Report Scope
  • 3.2 Disease Overview Epidemiology Overview
  • 3.3 Epidemiology

4 Marketed Drugs Assessment

  • 4.1 Marketed Drugs Overview
  • 4.2 Marketed Drug Profiles

5 Pipeline Assessment

  • 5.1 Pipeline Overview
  • 5.2 Pipeline Breakdown by Region
  • 5.3 Pipeline Breakdown by Molecule Type and Target
  • 5.4 Drug Review Designations
  • 5.5 Phase Transition Success Rates
  • 5.6 Likelihood of Approval

6 Clinical Trial Assessment

  • 6.1 Clinical Trials Overview by Phase
  • 6.2 Overview by Region
  • 6.4 Therapy Area Perspective
  • 6.4 Leading Sponsors
  • 6.5 Enrollment Analytics
  • 6.6 Feasibility Analysis

7 Commercial Assessment

  • 7.1 Upcoming Market Catalysts

8 Social Media and Digital Marketing

  • 8.1 Key Twitter Chatter
  • 8.2 Top Branded Websites
  • 8.3 Trust Flow and Citation Flow

9 Appendix

  • 9.1 Methodology
  • 9.2 About the Authors
  • 9.3 About GlobalData
  • 9.4 Contact Us
  • 9.5 Disclaimer